

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/559,982
				Filing Date	February 2, 2006
				First Named Inventor	Ruggero FARELLO
				Group Art Unit	1627
				Examiner Name	JAVANMARD, Sahar
				Confirmation No.	6583
Sheet	1	of	2	Attorney Docket No.	373987-011US (102895)

U.S. PUBLISHED DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Publication Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ²	
		Office	Number	Kind Code (if known)			Yes	No

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ²	
			Yes	No
	C109	OLANOW et al., "The scientific and clinical basis for the treatment of Parkinson disease (2009)," <i>Neurology</i> , Vol. 72 (Supple 4), pp. S1-S136 (2009). (Exhibit A to Second Declaration of C. Warren Olanow Under 37 C.F.R. § 1.132)		
	C110	OLANOW et al., "Modeling Parkinson's Disease," <i>Annals of Neurology</i> , Vol. 66, no. 4, pp. 432-436 (2009). (Exhibit B to Second Declaration of C. Warren Olanow Under 37 C.F.R. § 1.132)		
	C111	OLANOW et al., "An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment Guidelines," <i>American Academy of Neurology</i> , Vol. 56, pp. S1-S88 (2001). (Exhibit C to Second Declaration of C. Warren Olanow Under 37 C.F.R. § 1.132)		

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/559,982
				Filing Date	February 2, 2006
				First Named Inventor	Ruggero FARIELLO
				Group Art Unit	1627
				Examiner Name	JAVANMARD, Sahar
				Confirmation No.	6583
Sheet	2	of	2	Attorney Docket No.	373987-011US (102895)

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ²	
			Yes	No
	C112	MCCALL et al., "Sumanirole, a Highly Dopamine D ₂ -Selective Receptor Agonist: In Vitro and in Vivo Pharmacological Characterization and Efficacy in Animal Models of Parkinson's Disease," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 314, no. 3, pp. 1248-1256 (2005). (Exhibit D to Second Declaration of C. Warren Olanow Under 37 C.F.R. § 1.132)		

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or translation of abstract is attached.